Street Calls of the Week
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary at Twist Bioscience Corp (NASDAQ:TWST), sold 94 shares of common stock on September 15, 2025, at a price of $25.328, for a total value of $2380.
The sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by Twist Bioscience’s equity incentive plans. Following the transaction, Cho directly owns 102,943 shares of Twist Bioscience. The company, currently valued at $1.65 billion, maintains strong liquidity with a current ratio of 3.9 and has demonstrated robust revenue growth of 23% over the last twelve months. InvestingPro subscribers can access comprehensive insider trading analysis and 7 additional key insights about TWST’s financial health and market position.
In other recent news, Twist Bioscience reported a notable 18% year-over-year increase in revenue for Q3 2025, amounting to $96.1 million. Despite this revenue growth, the company recorded an adjusted EBITDA loss of $8 million, which marks an improvement from the previous fiscal year. Meanwhile, JPMorgan has adjusted its price target for Twist Bioscience to $25 from $33, maintaining an Underweight rating on the company. TD Cowen also revised its price target, lowering it to $36 from $58, while continuing to recommend a Buy rating. The firm attributed this change to adjusted fiscal year 2025 guidance due to a shift in Next-Generation Sequencing revenue. Evercore ISI followed suit by reducing its price target to $46 from $50, citing strong performance in the NGS segment and solid gross margin results. Additionally, Twist Bioscience has appointed Trynka Shineman Blake to its board of directors, where she will also serve on the audit committee.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.